Explora BioLabs Holdings, Inc. Sustainability Profile
Explora BioLabs Holdings, Inc., a leading provider in the preclinical research sector, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a key player in the biotechnology industry, specialising in high-quality in vivo and in vitro services. With operational facilities across major regions in the US, Explora BioLabs offers unique solutions that cater to the needs of pharmaceutical and biotech companies. The company’s core services include custom animal models, pharmacology studies, and toxicology assessments, all designed to accelerate drug development processes. Notably, Explora BioLabs has achieved significant milestones, including the expansion of its service offerings and strategic partnerships that enhance its market position. With a commitment to innovation and quality, Explora BioLabs Holdings, Inc. continues to support the advancement of life sciences research.
DitchCarbon Score
How does Explora BioLabs Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Explora BioLabs Holdings, Inc.'s score of 62 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Explora BioLabs Holdings, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Charles River Laboratories International, Inc., which means that any climate commitments or emissions data may be inherited from this parent organisation. As part of its corporate family relationship, Explora BioLabs aligns with the sustainability initiatives and targets set by Charles River Laboratories. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Charles River Laboratories. However, specific reduction targets or achievements for Explora BioLabs itself have not been disclosed. In summary, while Explora BioLabs Holdings, Inc. does not currently report its own emissions data or specific reduction targets, it is linked to the broader climate commitments of Charles River Laboratories, which may influence its sustainability practices and goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Explora BioLabs Holdings, Inc.'s Industry?
How Carbon Intensive is Explora BioLabs Holdings, Inc.'s Location?
Explora BioLabs Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Explora BioLabs Holdings, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
